GT Biopharma (GTBP) Competitors $1.07 -0.01 (-0.93%) Closing price 08/21/2025 04:00 PM EasternExtended Trading$1.10 +0.03 (+2.80%) As of 08/21/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GTBP vs. MIRA, NAII, CVKD, LSTA, RLYB, CING, ELEV, AYTU, BCAB, and ADAPShould you be buying GT Biopharma stock or one of its competitors? The main competitors of GT Biopharma include MIRA Pharmaceuticals (MIRA), Natural Alternatives International (NAII), Cadrenal Therapeutics (CVKD), Lisata Therapeutics (LSTA), Rallybio (RLYB), Cingulate (CING), Elevation Oncology (ELEV), Aytu BioPharma (AYTU), BioAtla (BCAB), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "pharmaceutical products" industry. GT Biopharma vs. Its Competitors MIRA Pharmaceuticals Natural Alternatives International Cadrenal Therapeutics Lisata Therapeutics Rallybio Cingulate Elevation Oncology Aytu BioPharma BioAtla Adaptimmune Therapeutics GT Biopharma (NASDAQ:GTBP) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk. Which has more volatility & risk, GTBP or MIRA? GT Biopharma has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, MIRA Pharmaceuticals has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Does the media prefer GTBP or MIRA? In the previous week, MIRA Pharmaceuticals had 2 more articles in the media than GT Biopharma. MarketBeat recorded 2 mentions for MIRA Pharmaceuticals and 0 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.50 beat MIRA Pharmaceuticals' score of 0.78 indicating that GT Biopharma is being referred to more favorably in the media. Company Overall Sentiment GT Biopharma Very Positive MIRA Pharmaceuticals Positive Do analysts rate GTBP or MIRA? GT Biopharma presently has a consensus price target of $11.00, indicating a potential upside of 928.04%. MIRA Pharmaceuticals has a consensus price target of $17.00, indicating a potential upside of 1,114.29%. Given MIRA Pharmaceuticals' higher probable upside, analysts clearly believe MIRA Pharmaceuticals is more favorable than GT Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do institutionals and insiders hold more shares of GTBP or MIRA? 8.2% of GT Biopharma shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 3.4% of GT Biopharma shares are held by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is GTBP or MIRA more profitable? MIRA Pharmaceuticals' return on equity of -406.70% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets GT BiopharmaN/A -1,804.34% -200.12% MIRA Pharmaceuticals N/A -406.70%-328.44% Which has better earnings and valuation, GTBP or MIRA? MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGT BiopharmaN/AN/A-$13.16M-$4.07-0.26MIRA PharmaceuticalsN/AN/A-$7.85M-$0.49-2.86 SummaryMIRA Pharmaceuticals beats GT Biopharma on 8 of the 11 factors compared between the two stocks. Get GT Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTBP vs. The Competition Export to ExcelMetricGT BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.84M$3.10B$5.80B$9.59BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-0.2620.1730.4025.20Price / SalesN/A375.37454.38114.90Price / CashN/A43.0937.1558.42Price / Book1.347.919.006.24Net Income-$13.16M-$54.72M$3.26B$265.30M7 Day Performance-20.15%0.84%0.67%-0.84%1 Month Performance-46.23%5.14%3.41%-1.53%1 Year Performance-50.46%10.15%29.23%17.73% GT Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTBPGT Biopharma2.5868 of 5 stars$1.07-0.9%$11.00+928.0%-50.0%$3.84MN/A-0.268Positive NewsGap UpMIRAMIRA Pharmaceuticals3.2312 of 5 stars$1.42+2.9%$17.00+1,097.2%-29.3%$23.35MN/A-2.782NAIINatural Alternatives InternationalN/A$3.70-0.1%N/A-27.7%$22.89M$113.80M-2.66290Gap DownHigh Trading VolumeCVKDCadrenal Therapeutics3.1324 of 5 stars$10.94-1.9%$32.00+192.5%+71.7%$22.82MN/A-1.184LSTALisata Therapeutics2.1294 of 5 stars$2.77+6.5%$23.50+748.4%-16.3%$22.76M$1M-1.2430Analyst ForecastRLYBRallybio3.0638 of 5 stars$0.50-6.4%$10.00+1,912.1%-47.9%$22.19M$640K-0.5340Short Interest ↓CINGCingulate2.4868 of 5 stars$4.05-2.9%$26.00+542.0%-63.7%$21.95MN/A-0.4820Earnings ReportShort Interest ↑ELEVElevation Oncology1.3978 of 5 stars$0.37flat$2.62+616.9%N/A$21.62MN/A-0.4540AYTUAytu BioPharma3.6264 of 5 stars$2.24-5.5%$10.00+346.4%-19.0%$21.27M$81M-3.11160Gap DownBCABBioAtla2.3059 of 5 stars$0.36+2.8%$5.00+1,279.3%-81.1%$20.60M$11M-0.3360ADAPAdaptimmune Therapeutics2.1082 of 5 stars$0.09+10.7%$1.35+1,475.4%-95.1%$20.54M$178.03M-0.32490Insider TradeGap Down Related Companies and Tools Related Companies MIRA Pharmaceuticals Alternatives Natural Alternatives International Alternatives Cadrenal Therapeutics Alternatives Lisata Therapeutics Alternatives Rallybio Alternatives Cingulate Alternatives Elevation Oncology Alternatives Aytu BioPharma Alternatives BioAtla Alternatives Adaptimmune Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GTBP) was last updated on 8/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access